(JNJ) stock has risen 60.6% over the past year, despite slipping 0.5% in the last week and 1.3% over the past month. Wall Street’s analysts are moderately bullish, forecasting further gains over the next twelve months with an average price target of $254.93 versus the last close of $240.10.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Analyst Asad Haider of Goldman Sachs & Co. LLC reiterated his Buy rating on Johnson & Johnson on April 15, 2026, setting an ambitious $275 price target. That implies meaningful upside from current levels and reflects his confidence that the company’s growth story is still in motion.
Haider’s note highlights that Johnson & Johnson has just delivered its fifth straight quarterly revenue beat, powered by its Innovative Medicines unit. Management also nudged 2026 guidance higher, and Haider suggests this may still be conservative given favorable profit dynamics and a stronger impact from new products in the second half of the year.
According to the report, J&J’s share price has closely followed rising sales estimates as new product cycles gain traction and drive a valuation re-rating. Management reiterated its goal of reaching double-digit revenue growth by the end of the decade and stressed that it does not need big acquisitions to get there, relying instead on its existing portfolio and pipeline.
Key products underpinning this optimism include Tremfya, which has been beating expectations by widening margins, and Icotyde, which management now frames as a potential $10 billion-plus product versus consensus nearer $7–8 billion. TipRanks shows Asad Haider as a highly-rated analyst, ranking 1,789 out of 12,125, with a 75.68% success rate and a 19.5% average return per rating. Never miss a stock rating. Find all the latest ratings on TipRanks’ Top Wall Street Analysts page.